Key Takeaways
- Treat-and-extend and PRN aflibercept regimens maintained visual and anatomical outcomes comparable to fixed monthly and bimonthly dosing in wet AMD.
- The treat-and-extend approach reduced injection frequency and required fewer clinic visits than PRN treatment.
Alternative aflibercept dosing regimens for wet age-related macular degeneration (AMD) may reduce treatment burden without compromising efficacy, according to a study. Investigators found that treat-and-extend (TAE) and pro re nata (PRN) regimens achieved similar visual and anatomical outcomes compared with fixed monthly or bimonthly dosing while requiring fewer injections.
The analysis included 7 randomized controlled trials involving 1,683 patients with wet AMD treated with intravitreal aflibercept.
No significant differences were observed between regimens in visual acuity or central retinal thickness outcomes. However, both TAE and PRN regimens significantly reduced injection frequency compared with monthly and bimonthly dosing schedules. Injection counts were not significantly different between the TAE and PRN approaches.
Investigators also reported that the TAE regimen was associated with fewer clinic visits than the PRN regimen.
Reference
Chen YS, Chang HC, Chi SC, et al. Different aflibercept regimens for wet age-related macular degeneration: A systematic review and network meta-analysis. J Chin Med Assoc. 2026;doi: 10.1097/JCMA.0000000000001379. Epub ahead of print. PMID: 41992419.
Related Content
